CGTN
The 19th Central Committee of the Communist Party of China (CPC) concluded its fifth plenary session in Beijing on Thursday with the release of a communique.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201029006395/en/
The 14th Five-Year Plan (FYP) (2021-2025) for National Economic and Social Development and the Long-Range Objectives Through the Year 2035 are the key topics of the communique.
Here is a look at all the highlights from the communique of the meeting.
Read the original article: here .
Decisive success made in building a moderately prosperous society in all respects
This year is the final year of China's 13th FYP period (2016-2020) and the communique highlighted that the implementation of the 13th FYP has been smooth.
By adhering to the new development concept and unswervingly advancing reform and opening-up, great achievements have been made since the fourth plenary session, the communique said.
During the past year, China has deepened supply-side reform, enhanced macro-economic regulation and expanded domestic demand as the strategic foundation.
Economic growth has been better than expected, people's livelihood has been improved and social stability has been maintained.
During the 13th FYP period, which is coming to an end in 2020, China has made great progress with stable economic growth and better economic structure, the communique said, noting China's GDP is expected to surpass the 100 trillion yuan ($14.9 trillion) mark in 2020.
More than 55 million people in China have been lifted out of poverty in the past five years.
China has built the world's largest social security system in the 13th FYP period, the communique said, adding that the country's basic medical insurance has covered over 1.3 billion people, and basic old-age insurance has covered nearly 1 billion people.
Meanwhile, during the past five years, more than 60 million new jobs were created in China's urban areas, it said.
As for the fight against the COVID-19 pandemic, the whole country coordinated the prevention and control work with economic and social development and put people's safety and health first.
Major country diplomacy with Chinese characteristics was vigorously promoted, and major achievements were made in various undertakings of the Party and state.
The strength of the leadership of the CPC and the Chinese socialist system has been further demonstrated in the past five years, it added.
New challenges, opportunities and proposals ahead
With regards to the blueprint for the future, the communique stressed that the whole Party must take into account the overall strategic plan for the great rejuvenation of the Chinese nation with major changes in the world that have not occurred in a century.
A thorough understanding is necessary about the new characteristics and requirements brought about by the changes in the evolution of the principal contradiction facing Chinese society, it said.
Also, given that China is in the primary stage of socialism, more attention should be paid to the new contradictions and challenges brought by the complex international environment.
The communique underlined the importance of strengthening awareness of opportunities and risks and cultivating opportunities amid crisis.
Additionally, the CPC has raised a set of long-range objectives for China to achieve socialist modernization by 2035.
China's economic, technological and composite strength was also stressed, as well as development in new industrialization and the modernization of China's system and capacity for governance.
The communique also said effort was needed in boosting the well-rounded development of society, including social etiquette and civility and the advancement of eco-friendly ways of work and life.
China's opening-up, per capita GDP, the implementation of the Peaceful China initiative and well-rounded human development were also highlighted.
As for the goals to be reached during the 14 FYP period, the communique said that the overall leadership of the CPC must be upheld to realize the 14th FYP and efforts should be made to mobilize all positive factors and rally all the forces that can be rallied to form a strong synergy to promote development.
Several proposals to reach the goals
- Upholding the central role of innovation in its modernization drive and implementing the innovation-driven strategy.
- Building a modern industrial system and upgrading the economic structure. It will continue to support the real economy, improve manufacturing power and modernized industrial chain and supply chain, so as to improve high-quality growth and core competitiveness.
- Nurturing a strong domestic market and establishing a new development pattern. The country will smooth domestic circulation and let domestic and international circulations reinforce each other, spurring consumption in an all-round way and expanding investment.
- Deepening reform comprehensively in pursuit of a high-level socialist market economy.
- Prioritizing the development of agriculture and rural areas, and fully advancing rural vitalization.
- Advancing coordinated regional development and a new type of urbanization.
- Promoting cultural sector and improving its cultural soft power.
- Accelerating green and low-carbon development, continuously improving the environment as well as the quality and stability of ecosystems, and raising the efficiency of resource utilization.
- Pursuing high-level opening-up and exploring new prospects of win-win cooperation.
It will continue to widen the opening-up and leverage the advantages of its huge market to promote international cooperation and achieve win-win results.
- Improving people's standard of living, and actively implementing strategies to address ageing population.
- Strengthening national security capabilities and increasing the capacity to deal with traditional and non-traditional security challenges, so as to protect people's lives and security and maintain social stability.
- Maintaining the long-term prosperity and stability of the Hong Kong and Macao special administrative regions, and promoting the reunification of Chinese mainland and Taiwan as well as peaceful Cross-Strait development.
It aims to keep a stable external environment and promote the building of a new type of international relations and a community with a shared future for mankind.
A total of 198 members and 166 alternate members of the CPC Central Committee attended the meeting.
Also present were members of the Standing Committee of the CPC Central Commission for Discipline Inspection and senior officials of relevant sectors, as well as experts, scholars and several deputies of the 19th CPC National Congress who work at the grassroots level.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201029006395/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
